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CHARACTERIZATION OF THE ROLE THAT BACTERIAL SURFACE 
POLYSACCHARIDE POLY N-ACETYL GLUCOSAMINE PLAYS IN 
NONVACCINE SEROTYPES OF STREPTOCOCCUS PNEUMONIAE 
COLONIZATION AND PATHOGENICITY 
 
FANNY JIANG 
 
ABSTRACT 
Poly N-acetyl glucosamine is a cell surface polysaccharide that has been 
characterized in Staphylococcus epidermidis and Staphylococcus aureus as involved in 
biofilm formation and implicated in virulence. Its role in bacterial colonization and 
pathogenicity is now being characterized in Streptococcus pneumoniae. The aim of this 
thesis was to produce PNAG-deficient S. pneumoniae mutants and to confirm differential 
levels of biofilm formation in PNAG-deficient mutants in comparison to their wild type 
strains. Using PCR, gel electrophoresis, and indirect immunofluorescence, successful 
transformations of PNAG-deficient mutants were confirmed. Biofilm assays provided 
preliminary data for further investigation of the role that PNAG plays in colonization in 
S. pneumoniae. A novel finding in PNAG genetic structure in S. pneumoniae was also 
discovered, providing a new avenue of research on PNAG.  
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INTRODUCTION 
 
Streptococcus pneumoniae is a major bacterial pathogen affecting children and 
adults worldwide. It is one of the common causes of otitis media (ear infections) in young 
children; and pneumonia, meningitis, and bacteremia in adolescents and adults. S. 
pneumoniae can also be found inhabiting the nasopharynx in healthy individuals and is 
generally cleared by the immune system without causing symptoms. These isolates are 
considered carriage isolates and the duration of carriage varies with age.  
S. pneumoniae generally causes disease in young children, the elderly, and 
immunocompromised individuals. In young children under 2 years of age, this is mainly 
due to underdevelopment of B-lymphocytes, the antibody-producing aspect of the 
adaptive response of the immune system, and thus diminished ability of antibody 
production against S. pneumoniae. Pneumococcal pneumonia is commonly caused by this 
bacterium in the elderly, especially those living in senior communities. Studies have 
shown that the decline in immune response against S. pneumoniae in the elderly can be 
attributed to age-related declines in spleen function causing loss of marginal zone B cells 
and macrophages (Birjandi & Witte, 2011). As an opportunistic pathogen, S. pneumoniae 
can cause serious invasive disease such as pneumonia, sepsis, and meningitis in 
susceptible individuals, such as those with compromised immune systems, who would 
otherwise not have adequate immune responses to clear the infection (Sanchez et al., 
2010). 
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I. Classification of Streptococcus pneumoniae 
S. pneumoniae is classified as a lancet-shaped, gram-positive, α-hemolytic, 
facultative anaerobic cocci bacterium that is often found in pairs (diplococci). They can 
also be observed singularly or in chains. There are at least 91 identified serotypes of S. 
pneumoniae, which are based on the unique polysaccharide antigen (capsule) found on 
the cell wall of the bacterium. The different serotypes are identified numerically 
(serotype 1, etc.) and capsules displaying similar antigenic serotype characteristics are 
designated a serogroup number and each are a designated a different letter (serotype 6A, 
6B, etc.) (Kasper & Fauci, 2010).
I.a. TIGR4 Genome as the Canonical S. pneumoniae Sequence 
 The first complete sequence of S. pneumoniae was achieved using the TIGR4 
strain by The Institute for Genomic Research (TIGR) (Bricker & Camilli, 1999). This 
was a highly virulent, serotype 4, encapsulated strain of S. pneumoniae. Since this strain 
was the first to be completely sequenced, its genome has been considered the canonical 
sequence with which sequences of other strains of S. pneumoniae are referenced against. 
In this thesis, the TIGR4 sequence was used as the reference genome of study.  
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I.b. S. pneumoniae as a Model Organism 
S. pneumoniae has been used as a reference organism for the study of genetics for 
decades. The first known genetics experiments using S. pneumoniae was conducted by 
Griffith in 1928 when he demonstrated the transfer of genetic material between two 
morphologically distinct strains of bacteria. He showed that the non-virulent strain was 
able to acquire the virulence characteristics of a virulent strain of bacteria (Griffith, 
1928). Griffith’s experiment was the first of its kind in demonstrating bacterial 
transformation. Since his discovery, later studies have shown S. pneumoniae to be 
naturally competent, or readily able to incorporate DNA from the environment and into 
its genome, and capable of natural genetic transformation (Burghout et al., 2007). This 
unique characteristic of S. pneumoniae makes it an ideal model organism to study the 
effects of genetic changes.  
 The ability of S. pneumoniae to become competent for genetic transformation is 
regulated by a two-component signal transduction system (TCS) and is activated by 
competence stimulating peptides (CSP) (Burghout et al., 2007). In order to stimulate 
competence, CSP is secreted into the environment from the S. pneumoniae bacterium 
during phases of exponential cell growth. The TCS, located in the cell envelope, detects 
the increasing levels of CSP, which then activates a signaling cascade that regulates the 
expression of genes that control DNA uptake, binding, and processing (Burghout et al., 
2007).  
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 Competence in S. pneumoniae can be stimulated by a variety of factors. In natural 
settings, some of these factors include stress responses, such as those against antibiotics, 
and during fratricide events (Burghout et al., 2007). During fratricide, neighboring cells 
become lysed due to the bacterial secretion of autolysin, releasing DNA to be taken up 
into the genomes of the surviving bacteria. Competence in response to stress allows for 
the acquisition of genetic elements that could potentially, for example, confer antibiotic 
resistance. In experimental settings, competence may be stimulated using synthetic CSP 
in order to produce greater transformation rates (Burghout et al., 2007).  
  After competence has been established and DNA has been taken up from the 
environment, acquired DNA becomes incorporated into the recipient cell genome. In 
natural genetic transformation, exogenous DNA is typically incorporated into the genome 
by homologous recombination, in which homologous or similar segments of the acquired 
and recipient DNA exchange (Lee, Seok, & Morrison, 1998). In experimental settings, 
many laboratory techniques have been designed to take advantage of the naturally 
occurring homologous recombination in order to artificially incorporate DNA into the S. 
pneumoniae genome. One technique is the insertion-duplication mutagenesis, in which a 
heterologous DNA can be incorporated into the S. pneumoniae genome (Lee et al., 1998). 
This technique is useful for gene knock out studies and for producing higher-yield 
transformations.  
 The ease at which S. pneumoniae achieves natural competence and its propensity 
to take up DNA from the environment makes it an ideal organism to conduct genetics 
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studies. S. pneumoniae allows researchers to incorporate specific gene mutations and 
manipulations into its genome, enabling study of those mutations and their effects with 
ease. 
 
I.c. S. pneumoniae Pathogenesis 
While S. pneumoniae is a commensal bacterium that can be found in a majority of 
adults without causing symptoms, it is also opportunistic and has the potential to cause 
serious disease in susceptible individuals. Colonization is an important determining factor 
in S. pneumoniae pathogenesis because it is thought to precede the development of 
invasive pneumococcal disease (IPD). It has been proposed that the prevention of 
bacterial colonization is a strong determinant of vaccine efficacy (Vernatter & Pirofski, 
2013). By inhibiting bacterial colonization and adherence to host tissues, S. pneumoniae 
invasion of host tissues can be prevented, thus preventing the development of disease.   
Since bacterial colonization precedes disease progression, factors that mediate 
colonization of host tissues, primarily the nasopharynx, may contribute to virulence. 
These include capsule switching, complement-binding evasion mechanisms, 
pneumolysin, choline-binding proteins, and biofilm formation. 
Capsule switching occurs in which S. pneumoniae strain exchanges DNA with a 
different capsular strain leading to acquisition of a potentially more virulent phenotype 
associated with the capsule from that of the donor strain (Vernatter & Pirofski, 2013). It 
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has been shown that capsular switching events can result in S. pneumoniae strains with 
enhanced virulence of respiratory tract infections (Sabharwal et al., 2014).  
One host immune response that is protective against bacterial colonization is 
complement-mediated phagocytosis. Recent studies have shown that S. pneumoniae 
expresses several genes that impair complement deposition, leading to increased 
colonization and pneumococcal invasiveness (Vernatter & Pirofski, 2013). In one study 
on complement evasion, it has been shown that reduced complement deposition on 
invasive strains of S. pneumoniae led to a increased occurrence of experimental otitis 
media (EOM) in chinchilla models following nasopharyngeal colonization and 
barotrauma (Sabharwal, Ram, Figueira, Park, & Pelton, 2009). 
Another factor involved in S. pneumoniae colonization is pneumolysin (PLY). 
This toxin is known to cause host cell lysis, increased lung permeability, and impaired 
bacterial clearance (Vernatter & Pirofski, 2013). Biofilm formation has also been found 
to influence colonization of the nasopharynx. Various bacterial surface proteins such as 
serine-rich repeat proteins (PsrP) and choline binding proteins (CBPs) have been 
identified as involved in biofilm formation due to their abilities to promote bacterial 
aggregation and cell adhesion (Vernatter & Pirofski, 2013). CBPs are anchored to the cell 
surface and have been implicated in virulence. Some CBPs include several hydrolytic 
enzymes such as LytA, which causes release of inflammatory products that cause cell 
wall degradation and pneumolysin secretion; LytB, LytC, and CpbE, which have also 
been found to be involved in nasopharyngeal colonization (Mitchell & Mitchell, 2010). 
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Shown in Figure 1 are examples of various virulence factors known to be involved in 
mouse models of pneumococcal disease. The effects of these virulence factors are mainly 
to facilitate an increased ability for S. pneumoniae to colonize.  
 
 
Figure 1. S. pneumoniae Surface Molecules Shown to be Virulence Factors in Mouse 
Models of Pneumococcal Disease. Hypothetical image representing various cell surface 
molecules shown to be involved in causing virulence in mice. These surface antigens 
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have been shown to produce protective immune responses in mice (adapted from Briles 
et al., 1998).   
Once S. pneumoniae has successfully colonized the mucosa, two events typically 
occur: immune clearance or disease progression. In healthy individuals, the immune 
system will clear the bacteria without any complications. In susceptible individuals 
(young children, elderly, and immunocompromised), the immune system may not 
produce a sufficient response against the bacteria, thus allowing S. pneumoniae to breach 
the protective barriers, enter a sterile environment, and cause disease.  
S. pneumoniae causes a variety of inflammatory responses in the body that are 
mediated by host receptor signaling pathways, innate, and adaptive immune responses. In 
mice, when the bacteria enters the lungs, binding to the Toll-Like Receptor 2 (TLR2) 
triggers a signaling cascade that leads to inflammation. Although it has been previously 
thought to be a primarily antiviral defense, type I interferon (IFN1) secretion has been 
found to also be induced by bacteria infected cells. In one study, it was shown that S. 
pneumoniae infected cells induce the secretion of IFN1 from the macrophages of infected 
mice, which then acted to regulate T cell recruitment (Koppe et al., 2012). However, it 
was found that during co-infection with influenza, IFN1 release impaired macrophage 
recruitment, leading to greater bacterial growth in increased host cell damage (Vernatter 
& Pirofski, 2013). These findings show that viral infection negatively affects immune 
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responses against S. pneumoniae and creates an environment more permissive to bacterial 
infection.  
In order to fight a pneumococcal infection, both innate and adaptive immune 
systems are activated to clear the bacteria. The innate immune response to S. pneumoniae 
involves the recruitment of macrophages, neutrophils, and other polymorphonuclear 
leukocytes to the site of infection to phagocytize the invading bacteria. Adaptive 
immunity responses involve CD4+ and CD8+ T cell recruitment to the site of infection. 
Malley and colleagues found that the presence of CD4+ T lymphocytes was necessary to 
produce a protective effect against S. pneumoniae following immunization with whole 
cell vaccine (killed acapsular pneumococci and conjugated to cholera toxin) and antibody 
independent (Malley et al., 2005). The researchers also found that CD8+ T cell-deficient 
mice were still protected following immunization, suggesting that CD8+ T lymphocytes 
are not necessary for developing immune protection against S. pneumoniae. Although 
they may not be shown to contribute to developing immunity, CD8+ T cells recruited to 
sites of infection mediate inflammatory response through the activation of IFN-γ and 
cytokines (Vernatter & Pirofski, 2013).
I.d. Polysaccharide Capsule as a Virulence Factor
Among the different virulence factors contributing to the ability of S. pneumoniae 
to cause disease, the polysaccharide capsule remains one of the most important and 
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extensively studied. The polysaccharide capsule is composed of repeating 
oligosaccharides with organic and inorganic molecules interspersed within the structure 
(Boone, Castenholz, & Garrity, 2001). It has been shown that variations in virulence, 
nasopharynx colonization, and ability to cause invasive disease to be serotype-related. 
The capsule contributes to antiphagocytic activity by preventing bacterial antigens from 
interacting with immune cells, thus inhibiting phagocytosis by phagocytes. It also plays 
an important role in the colonization of the nasopharynx, prevention of removal by 
mucus, restriction of autolysis, and reduction of contact with antibiotics (Mitchell & 
Mitchell, 2010). In addition, it has been found that the capsule contributes to invasive 
disease by allowing the bacteria to escape mucus entrapment and thereby reach the 
underlying epithelial layer where colonization then takes place (Nelson et al., 2007). 
I.d.i. Pneumococcal Polysaccharide Vaccine 
A pneumococcal polysaccharide vaccine approved for protection against S. 
pneumoniae was first licensed for use in the 1980s and still currently administered. This 
vaccine contained capsular polysaccharide antigen from 23 different serotypes. The 23-
valent pneumococcal polysaccharide vaccine (PPV23) is typically recommended for 
healthy adults 65 years of age and older, individuals 2 years of age with increased 
susceptibility to pneumococcal disease (Greene et al., 2006). Vaccine efficacy for the 
current PPV23 has been estimated to be 44% effective at preventing IPD in adults over 
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65 years of age and as high as 61% effective at preventing IPD in adults age 2 and older 
(Greene et al., 2006).
 
I.d.ii Disadvantages of the Pneumococcal Polysaccharide Vaccine
Although the PPV23 has been successful at reducing the incidence of invasive 
pneumococcal disease in children and adults ages 2 years and older, there are still some 
issues. PPV23 does not protect infants under the age of 2 because their underdeveloped 
immune systems cannot adequately produce protective antibodies against the antigens in 
the vaccine (Miyaji, Oliveira, Carvalho, & Ho, 2013). PPV23 also does not effectively 
reduce the carriage rate of S. pneumoniae because it does not elicit an immune response 
against the carriage bacteria residing in the nasopharynx (Veenhoven et al., 2004). 
I.d.iii. Pneumococcal Conjugate Vaccine 
A second pneumococcal vaccine was licensed for use in the United States in 2000 
and it contained 7 polysaccharide capsule antigens of the most prevalent serotypes (4, 6B, 
9V, 14, 18C 19F, and 23F) conjugated to a non-toxic diphtheria toxin with an aluminum 
adjuvant. After the PCV7 was introduced in the United States, it was found that the 
frequency of physician visits due to acute otitis media (AOM) was reduced significantly 
(Kaplan et al., 2015). Additionally, it was shown that of the serotypes causing AOM, the 
proportion of vaccine serotypes was significantly reduced. These findings show that the 
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PCV7 is effective against preventing pneumococcal disease, particularly AOM, caused 
by vaccine serotypes.  
However, the effectiveness of PCV7 against the vaccine serotypes allowed for 
other non-vaccine serotypes that were not targeted by the vaccine to become more 
problematic in the population. For example, serotype 19A became the leading cause of 
AOM and mastoiditis in children following the introduction of PCV7 (Kaplan et al., 
2015). Consequently, the PCV was later expanded in 2010 to include an additional 6 
serotypes (1, 3, 5, 6A, 7F, and 19A) to protect against a total of 13 serotypes of S. 
pneumoniae. According to one randomized trial conducted over a 3-year period in 2011 - 
2013, isolates obtained from middle ear and mastoid cultures were found to have a 
reduced proportion of PCV13 serotypes (2011, 50%; 2012, 40.5%; 2013, 29%) In 
addition, the proportion of serotype 19A found in the population also declined by 76% 
over the same 3-year time period (Kaplan et al., 2015). This observable decline in the 
proportion of vaccine serotypes shows that the PCV13 is effective at reducing the 
proportion of vaccine strains in the population.  
Its effectiveness in reducing disease has been observed by marked reductions in 
IPD in both individuals vaccinated and unvaccinated with the PCV. These reductions in 
disease were in part due to the effectiveness of the vaccine in reducing carriage 
colonization of vaccine serotypes and also promoting herd immunity, in which 
unvaccinated children were protected from disease transmission due to protection in 
vaccinated children (Yildirim et al., 2015).
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I.d.iv. Disadvantages of the Pneumococcal Conjugate Vaccine 
While PCV13 is very effective at preventing invasive disease caused by vaccine 
serotypes and has since also reduced the carriage rate of vaccine serotypes in the 
population (although overall carriage rates have remained the same), it has created a 
competitive pressure in which non-vaccine serotypes have emerged in the population and 
replaced the previously prevalent serotypes (replacement disease) (Casey, Adlowitz, & 
Pichichero, 2010). One solution to address that particular problem would be to expand 
the current PCV to include capsule antigens of the emergent serotypes. However, that 
would continue the process of competitive pressure for non-vaccine serotypes to become 
more prevalent and virulent. A different approach must be taken that is independent of 
the polysaccharide capsule in order to target S. pneumoniae of all serotypes.
I.e. Alternative Approaches to Current Pneumococcal Vaccines 
As research has shown, vaccines that target the capsule polysaccharide have some 
disadvantages such as replacement disease due to non-vaccine serotypes and the 
ineffectiveness of these vaccines at reducing carriage rates in the nasopharynx. Recent 
efforts have been focused on investigating non-capsular factors universal to S. 
pneumoniae that contribute to pathogenicity, especially those that are involved in host 
colonization. Since colonization must be established before disease occurs, preventing 
bacterial colonization of the nasopharynx is hypothesized to prevent disease 
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development. Targeting the factors involved in colonization would make an ideal non-
serotype specific vaccine, and understanding the underlying mechanisms to colonization 
would be able to elucidate alternative methods of protecting against S. pneumoniae 
(Munoz-Elias, Marcano, & Camilli, 2008). 
 
I.f. Colonization as a Precursor to Pneumococcal Disease Development: Biofilm  
The ability to colonize and persist in the nasopharynx and to form biofilm is an 
important subject currently being investigated in S. pneumoniae. Biofilms consist of 
communities of bacterial cells that produce a structured extracellular matrix composed of 
proteins, polysaccharides and DNA (Figure 2). A defining feature of biofilms is their 
ability to provide increased resistance against antimicrobials. This is accomplished 
through an increased tolerance to the antibacterial agents rather than the acquisition of 
genetic mutations (Chao et al., 2015). Biofilms also act as a protective environment 
allowing for increased evasion of host immune responses, enabling persistence of 
bacteria in the host and also dissemination of bacteria to other tissues (Chao et al., 2015). 
These protective and host-evading properties suggest that biofilm-producing bacteria may 
be more effective at colonizing tissues, which could possibly lead to disease 
development.   
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 Figure 2. Scanning Electron Micrographs Depicting S. pneumoniae Morphology.  
(A) Representative image showing biofilm formed on mouse epithelial mucosa in vivo. 
(B) Biofilm grown on mouse epithelial cells in vitro. (C) Biofilm formed on glass media. 
ECM: extracellular matrix; RBC: red blood cell; Spn: S. pneumoniae (adapted from Chao 
et al., 2015).  
Recent studies in other bacterial species have found biofilm formation to be 
important in establishing colonization and chronic respiratory infections in organisms 
such as Pseudomonas aeruginosa and Staphylococcus aureus (Munoz-Elias et al., 2008). 
Other streptococci have been shown to produce biofilm, such as those that colonize the 
oral cavity including, Streptococcus mutans, Streptococcus gordonii, and Streptococcus 
intermedius, which form biofilm on the surfaces of teeth. Streptococcus pyogenes has 
also been demonstrated to adhere to mucosal epithelial cells, which suggests biofilm 
formation to play a role (Munoz-Elias et al., 2008).  
Some studies in S. pneumoniae have examined the role that biofilm plays in 
colonization and disease progression. One study has shown a direct correlation between 
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biofilm formation and colonization ability in the mouse nasopharynx (Chao et al., 2015). 
These high biofilm-producing strains were found to be better colonizers and also 
developed greater antibacterial resistance than the more invasive strains that were shown 
to be less effective colonizers. Although it is well known that bacterial colonization 
always precedes infection, the mechanism that underlies that transition is still unclear.  
Different proposals have been made about the progression from biofilm 
colonization to infection, including the involvement of viral infections, host environment 
changes, and phenotypic changes that induce dispersion of bacteria from biofilm. Since 
viral infections are frequently associated with pneumococcal bacterial infections, either 
preceding or occurring concurrently, it has been suggested that the two types of infections 
are associated. It has also been demonstrated in vivo the dissemination of pneumococci 
from biofilm colonizing the nasopharynx and into the middle ear or lungs in response to 
host signals such as ATP, norepinephrine, glucose, and febrile-range-hyperthermia (FRH) 
(Chao et al., 2015). In addition, it has been shown that the bacteria that become dispersed 
from biofilms express a unique phenotype different from that of cells growing freely and 
not adhered to biofilm (planktonic) or that of bacteria grown in broth (Chao et al., 2015). 
These actively dispersed bacteria tend to be more virulent than the bacteria found in the 
biofilms. These findings suggest an underlying mechanism, possibly stimulated by viral 
infection, that induces a transcriptional expression change resulting in virulent bacteria 
capable of dispersing from biofilm and into sterile tissues. 
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I.g. PNAG as a Virulence Factor Involved in Biofilm Formation in Other Bacteria 
One potential virulence factor that has been identified as involved in biofilm 
formation in Staphylococcus epidermidis is the cell surface polysaccharide, β1-6-linked 
poly N-acetyl glucosamine (PNAG). PNAG is an important subject of vaccine research 
because it has been shown to be expressed on the cell surfaces of a wide variety of gram 
positive and gram negative prokaryotes and eukaryotes including Staphylococcus aureus, 
Streptococcus pyogenes, Clostridium difficile, S. pneumoniae and many other pathogenic 
microbes (Cywes-Bentley et al., 2013).  
PNAG has been widely studied in S. aureus. PNAG is encoded by the genes 
icaADBC of the intercellular adhesin locus in S. aureus. In one study, the icaB gene, 
believed to be responsible for N-deacetylase activity, was found to be involved in biofilm 
formation in S. aureus. icaB deletion mutants were shown to be unable to express any 
detectable PNAG and produced very little biofilm in vitro as compared to the moderately 
ica-expressing S. aureus strain, which expressed an intermediate amount of cell surface 
associated PNAG and produced a moderate amount of biofilm in vitro. The icaB over-
expressing S. aureus strain produced a greater amount of cell surface-associated PNAG 
and produced biofilm in vitro four-fold greater than the moderately ica-expressing 
parental strain (Cerca et al., 2007). The researchers were able to show that differences in 
PNAG expression resulted in differing levels of biofilm formation, which suggests an 
involvement of PNAG in biofilm formation in S. aureus.  
  
 
18
One mouse model of bacteremia study demonstrated that the surface PNAG-
deficient S. aureus strains had reduced survivability in the blood of infected mice due to 
enhanced antibody-independent opsonic killing, while the strains with an overexpression 
of cell surface PNAG resulted in a greater survivability in the blood. This shows that the 
presence of surface PNAG resulted in greater protection against antibody-independent 
opsonic killing (Cerca et al., 2007). This mouse model of bacteremia study and biofilm 
findings in S. aureus strongly suggests that PNAG plays an important role in invasiveness 
and establishing persistence in the host and therefore a possible role in pathogenicity and 
virulence in bacteria. 
I.h. PNAG as a Potential Virulence Factor in S. pneumoniae  
Although the effects of PNAG on biofilm formation and opsonic protection are 
becoming elucidated in other bacteria such as S. aureus, there is still a lack of literature 
on its role in S. pneumoniae. In one study, an in vitro mutant screen for S. pneumoniae 
mutants that impair biofilm formation was conducted to identify genes possibly involved 
in biofilm formation. Munoz-Elias et al. identified 69 mutants in acapsular strains of S. 
pneumoniae that resulted in altered biofilm formation including one containing a 
mutation in the gene locus encoding PNAG (SP0698). This mutation caused reduced 
biofilm formation in acapsular strains (Munoz-Elias et al., 2008). Further research is 
necessary in order to appropriately confirm the role of PNAG in biofilm formation in S. 
pneumoniae.  
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The potential that PNAG may be a virulence factor involved in biofilm formation 
presents an alternative approach to currently available pneumococcal vaccines in 
preventing pneumococcal disease. Since biofilm is considered a good indicator of 
bacterial colonization in many bacterial genera including that of Streptococcus, it can be 
proposed that by disrupting key factors involved with biofilm formation, colonization can 
then be prevented, which could lead to interference of disease development. I hypothesize 
that if PNAG is involved in biofilm formation in S. pneumoniae, then the disruption of 
PNAG expression and function will result in decreased levels of biofilm formation. 
Further investigation should then be conducted in animals to assess virulence and 
pathogenicity of PNAG-deficient S. pneumoniae with future directions in immune 
response studies and vaccine development.  
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METHODS 
 
II.a. Bacterial Strains Used
S. pneumoniae strains 353 (serotype 4), 2394 (acapsular), 3195 (acapsular) a 
PNAG-defective mutant, 3185, and 3213 (acapsular) were obtained from Camilli and 
colleagues at Harvard University. Strain 353 is a streptomycin-resistant (SmR) strain 
derived from a TIGR4 clinical isolate. Strain 2394 is an acapsular mutant of strain 353. 
Strains 3185, 3213, and 3195 are streptomycin and spectinomycin-resistant (SpR) 
transposon mutants derived from the 2394 acapsular strain, in which the genes SP0695, 
SP0696, and SP0698, respectively, were interrupted by the insertion of the Magellan 5 
transposon according their previously described technique (Hava & Camilli, 2002). The 
Magellan 5 transposon contained a marker conferring SpR to allow for selection. The 
transposon interruption in strain 3195 disrupts its functional expression of PNAG, 
confirmed by indirect immunofluorescence assays. The transposon interruptions in strains 
3213 and 3185 disrupted putative gene products. It should be noted that the S. 
pneumoniae gene sequences were based on the TIGR4 genome sequence.  
S. pneumoniae strains 1230 and 159 (non-vaccine serotype 35B) were acquired 
from clinical isolates obtained from the Department of Pediatrics at Turku University 
Hospital in Turku, Finland (Tahtinen, Laine, Ruuskanen, & Ruohola, 2012). FJ002 
(vaccine serotype 19A), and FJ003 (non-vaccine serotype 16F) were naturally 
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transformed SmR mutants selected from parental strains, MD5033 and PT8090, 
respectively. These parental strains were selected from clinical isolates obtained by the 
Boston Medical Center Department of Pediatric Infectious Diseases. S. pneumoniae 
strains FJ004 (FJ002 background) and FJ005 (FJ003 background) are both SpR and 
SmR. FJ001 (1230 background) is only SpR.  These three strains were constructed from 
their respective parental strains by introducing the transposon-interrupted SP0698 gene 
(SP0698::Magellan 5) isolated from strain 3195 using a transformation technique adapted 
from methods previously described by Nahm and colleagues (see Methods Section II.f.) 
(Calix et al., 2011). Mutant strains containing SP0698::Magellan 5 will henceforth be 
called “PNAG mutants” or “mutants.” 
Other bacterial strains used were selected from the nasopharyngeal collection of 
clinical isolates obtained by the BMC Department of Pediatric Infectious Diseases: R34-
3203 (11A), LE4018 (11A), and PT8037 (11A) (Table 1). 
Table 1. Bacterial Strains Used  
Strain 
Number 
Strain Name Serotype Phenotype 
353 TIGR4 4 SmR 
2394 353 ΔcpsA-cps4L Acapsular SmR 
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3185 353 SP0695::magellan5 Acapsular SmR, SpR, putative gene 
product 
3195 353 SP0698::magellan5 Acapsular SmR, SpR, PNAG non-
expressing 
3213 353 SP0696::magellan5 Acapsular SmR, SpR, putative gene 
product 
1230 1230 35B  
FJ002 MD5033 SmR 19A SmR 
FJ003 PT8090 SmR 16F SmR 
FJ001 1230 SP0698::magellan5 35B SmR, SpR, PNAG non-
expressing 
FJ004 MD5033 SP0698::magellan5 19A SmR, SpR, PNAG non-
expressing 
FJ005 PT8090 SP0698::magellan5 16F SmR, SpR, PNAG non-
expressing 
159 159 35B  
LE4018  LE4018 11A  
PT8037 PT8037 11A  
R34-3203 R34-3203 11A  
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Bacterial strains were described in the thesis by their strain number and their 
corresponding bacterial names listed were assigned according to their genomic 
background and genetic manipulations.
II.b. Transposon Mutagenesis 
A transposon mutant, 3195, was used as the source of the donor mutant SP0698 
allele for the transformation procedures and was acquired from Camilli and colleagues at 
Harvard University. This mutant contained a transposon (transposable element) that was 
inserted via a transposase catalyzed transposition reaction (Munoz-Elias et al., 2008). By 
inserting a transposon into a gene, the expression and function of that gene product 
becomes disrupted. Successful transformation can also be confirmed by selecting for the 
spectinomycin resistance marker contained in the transposon. This transposon mutant 
was used as our transformant donor DNA because of the ease with which homologous 
recombination can be achieved using competent S. pneumoniae and also because mutants 
can be easily selected using the antibiotic resistance marker. 
II.c. Bacterial Growth Conditions  
S. pneumoniae was grown on blood agar plates (BAP) (Remel) from frozen 
bacterial stocks stored at -80°C and incubated overnight in CO2 candle jars at 37°C. 
Single colonies were selected, inoculated in either brain heart infusion broth (sBHI) 
(Remel) supplemented with hemin (from filter-sterilized horse blood) and NADH or 
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Todd Hewitt broth (THY) (Fluka) supplemented with 1% yeast (Fisher Scientific), and 
grown overnight at 37°C. Antibiotic concentrations used were as follows: streptomycin 
(Fisher) at 200 ug/ml and spectinomycin (Fisher) at 200 ug/ml. 
II.d. Bacterial DNA Extraction
 S. pneumoniae was grown according to the above growth conditions in sBHI. 
Genomic bacterial DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen) 
according to manufacturer instructions. After concentrating bacterial cultures by 
centrifugation at 7500 rpm for 10 minutes (Eppendorf), DNA extraction was achieved by 
degrading the cell wall, cellular proteins, and other cellular substituents using lysozyme 
derived from chicken egg white (Sigma) and Proteinase K (Qiagen). Bacterial RNA was 
degraded using RNase A (Qiagen). Impurities and contaminants were then removed using 
manufacturer wash buffers and applied onto the silica-based membrane DNeasy spin 
column (Qiagen). Bacterial genomic DNA was then eluted from the column into tris-
EDTA buffer (pH 8) (Ambion). DNA concentration was determined by 
spectrophotometry using the NanoDrop ND-1000 (Thermo Scientific) to detect nucleic 
acids at 260 nm and DNA purity was assessed using the ratio of 260 nm/ 280 nm. 
II.e. Polymerase Chain Reaction (PCR) DNA Amplification
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 The gene locus encoding PNAG, SP0698, was amplified from bacterial genomic 
DNA using the Expand Long Range dNTPack (Roche) PCR kit. Amplification was made 
using forward primer, SP0698_1473 (Eurofins Genomics), melting temperature: 62.4°C; 
and reverse primer, SP0698_5370, melting temperature: 62.4°C (Eurofins) (Table 2). The 
PCR was carried out using the MyCycler Thermal Cycler (Bio-Rad) according to the 
conditions outlined in Table 3. The final PCR amplification products were then treated 
using the QIAquick PCR Purification Kit (Qiagen) to remove impurities and PCR 
reagents. 
Table 2. Primers Used to Amplify Gene Encoding PNAG (SP0698)  
Primer Sequence 
Melting 
Temperature 
SP0698_1473  
(forward) 
5’-TGCCTGCTATTTTGGGAGGG3’ 62.4°C 
SP0698_5370  
(reverse) 
5’-CAGCTTGGGTAATGGGACGT-3’ 62.4°C 
SP0698_1875 
(forward) 
5’-CGGGCACTTATCAGCCAACC-3’ 64.5°C 
SP0698_4608 
(reverse) 
5’-ACCTTAGCTGCCTCTCTGGA-3’ 62.4°C 
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Table 3. Polymerase Chain Reaction Cycle Conditions
PCR Step Temperature Time (m:ss) Cycle Repeat 
Denaturation 92°C 2:00 1x 
Denaturation 92°C 0:10 
10x Annealing 60°C 0:30 
Elongation 68°C 6:00 
Denaturation 92°C 0:10 
25xa Annealing 60°C 0:30 
Elongation 68°C 6:00 
Final Elongation 68°C 7:00 1x 
Final Hold 8°C ∞ 1x 
a Temperature was increased every 0:20.
II.f. Agarose Gel Electrophoresis 
 The amplified PNAG gene segment was then electrophoresed on 0.8% agarose 
gels (Fisher) in 1xTAE buffer (Thermo) with 5uL GreenGlo Safe DNA Dye 20,000X 
(Denville) to stain the DNA, and TriDye 1kb DNA Ladder (New England Biolabs) was 
used as a weight marker and Gel Loading Dye 6x (NE Biolabs) was used to label the 
PCR amplification products. Electrophoresis was performed in 1xTAE buffer in an 
electrophoresis chamber (Denville) at 110 V. The gel was then visualized using the Blue 
Pearl Transilluminator (Pearl Biotech).
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II.g. Bacterial Transformation 
II.g.i. Competent Cells Production
 To produce competent cells, S. pneumoniae was grown on BAP overnight in 
37°C. A single colony was then selected and grown in 5 ml competence media (CM) 
(THY with 0.2% glucose [MP Biomedics]; 0.2% bovine serum albumin [BSA] [Fisher]; 
and 0.02% CaCl2 [Fisher]), and incubated to an optical density (OD)600= ~0.4 (~5 hours) 
at 37°C on a rotator. For slow growing strains, this procedure was modified by growing 
the competent cells at 30°C for 10 hours, with shaking. Competent cells were grown in 
sterile 15ml polystyrene centrifuge tubes (Denville). Following incubation, the competent 
cells were concentrated and 250ul aliquots were made from each tube added to 20% 
glycerol and stored in sterile 2 ml cryotubes (Corning) at -80°C. 
II.g.ii. Bacterial Transformation with SP0968::Magellan5 
 Frozen aliquots of S. pneumoniae were then thawed in 1ml of warmed, freshly 
prepared CM with added competence stimulating peptide (CSP) added to reach the 
following final concentrations: 2 ug/ml CSP-1 (5mg/ml stock); 2ug/ml CSP-2 (1 mg/ml 
stock) (Bio-Synthesis). The competent cells were then transferred into sterile 
microcentrifuge tubes (Eppendorf) and centrifuged at 8000 rpm for 10 minutes. The 
supernatant was discarded and the competent cells were re-suspended in 400 ul CM with 
added CSP by pipetting up and down. Each 400 ul tube was then divided into 2-200 ul 
aliquots—one labeled “control” (no DNA added) and one labeled “transformation” (DNA 
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added). The cultures were then incubated at 37°C for 14 minutes. Following the 
incubation period, 2 ug/ml of the purified SP0968::Magellan5 PCR product was added to 
the microcentrifuge tube labeled, “transformation.” No PCR product was added to the 
microcentrifuge tube labeled, “control.” Both microcentrifuge tubes were then incubated 
at 37°C in the Thermomixer microincubator (Eppendorf) for 3 hours, no shaking. 
II.g.iii. PNAG Mutant Selection and Confirmation 
Positive PNAG mutants conferring spectinomycin resistance (SP0698::Magellan5 
selective marker) were then selected by plating the “transformation” tube on 200 ug/ml 
spectinomycin BAP. The contents of the “control” tube were halved, with 100 ul plated 
on 200 ug/ml spectinomycin BAP and 100 ul plated on BAP with no antibiotics added. 
The plates were incubated overnight at 37°C in a CO2 candle jar. Potential positive 
PNAG mutants were then selected and grown on 200 ug/ml spectinomycin BAP to 
confirm spectinomycin resistance. Stocks of potential positive PNAG mutants were then 
created from lawn growth and stored in cryotubes at -80°C. Bacterial DNA extraction, 
PCR amplification, and agarose gel electrophoresis were then performed to confirm 
positive transformation with PNAG.
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II.h. Biofilm Assay 
S. pneumoniae strains 2394, 3213, 353, and 3195 were grown on BAP overnight 
in CO2 candle jars. The following day, a single colony was selected and inoculated in 3 
ml warmed sBHI broth. The cultures were then incubated at 37°C, no shaking, to mid-log 
phase (~4 hours). Each S. pneumoniae strain was then inoculated using a multi-channel 
pipet into a 96-well polystyrene tissue culture plate (100ul/well) (Corning) prepared with 
100ul/well of sBHI with glucose added to reach a final concentration of 5% glucose. The 
96-well polystyrene tissue culture plates were then incubated in CO2 candle jars at 37°C 
for 18 hours. Following incubation, cell density was measured using EMax Plus 
Microplate Reader (Molecular Devices) at 595 nm. The optical density of the bacterial 
growth was measured and recorded using SoftMax Pro6 software (Molecular Devices). 
The plates were then gently washed three times with deionized water using the 
MultiWash+ Microplate Washer (Molecular Devices). 
II.h.i. Crystal Violet Stain to Measure Biofilm Production 
The washed 96-well plates containing biofilm growth were then air-dried at 37°C 
for ~3 hours or until fully dried. Next, 50 ul of 0.06% crystal violet (CV) (Aqua 
Solutions) stain was added to each well and incubated for 30 minutes at room 
temperature. The 96-well plates were then gently washed three times with deionized 
water to remove excess CV. Then, 50 ul of 30% acetic acid (AA) (Fisher) was added to 
each well to solubilize the CV-stained biofilm. After gently shaking the plates to 
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thoroughly distribute the CV and AA mixture, the optical density of each well was 
measured at 595 nm to determine levels of biofilm production.   
II.h.ii. DAPI Stain to Confirm Presence of DNA in Biofilm 
4',6-diamidino-2-phenylindole (DAPI) (Thermo) is a fluorescent stain that is used 
to label the A-T-rich regions of DNA. This part of the assay was used to determine the 
presence of intracellular and extracellular DNA in the biomass produced by the bacteria. 
Following the plate washing, the plates were then fixed using 2% paraformaldehyde 
(50ul/well) (Affymetrix) and incubated for 30 minutes. Next, the paraformaldehyde was 
removed from the wells and discarded into the appropriate waste container. DAPI 
(1ug/ml) was then added to each well (50 ul/well). Following the DAPI staining, the 
plates were immediately wrapped in aluminum foil to prevent photo-bleaching of the 
DAPI stain. The plates were then visualized using fluorescence microscopy.  
II.i. Indirect Immunofluorescence Assay 
Analysis of PNAG expression was conducted using immunological detection of 
PNAG on the cell surface with a primary antibody solution to PNAG (human IgG mAb 
F598) described previously (Cerca, et al 2007). Briefly, S. pneumoniae strains were 
grown as described above on BAP and bacteria were swabbed directly off plate onto 
glass slides to produce a thick coat on the slide surface. The slides were then to air dried 
and fixed for 1 min at room temperature with ice-cold methanol. The slides were then 
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labeled with 5.2 ug/ml of F598 directly conjugated to Alexa Fluor 488 overnight at 4°C 
in a humid chamber and 500nM Syto83 (nucleic acid stain) for one hour at room 
temperature. Samples were washed and mounted for confocal. Slides were examined by 
confocal microscopy with a Zeiss LSM5 Pascal instrument equipped with a 
krypton/argon laser. Images were analyzed with PASCAP software (version 5; Zeiss). 
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RESULTS 
 
III.a. Optimization of Bacterial Transformation Procedure 
The bulk of this project was spent on performing DNA transformation 
experiments to produce PNAG-deficient S. pneumoniae mutants. This process was 
adapted from a procedure shared with us by Nahm and colleagues at the University of 
Alabama and continuously amended to optimize results (Calix et al., 2011). There were 
some obstacles to achieving successful transformations due to the use of new 
transformation reagents and also due to the use of clinical isolate strains of S. 
pneumoniae. It was found that implementing several changes improved transformation 
success.   
The S. pneumoniae strains used were non-vaccine serotypes selected from 
laboratory clinical isolates. After several trials of unsuccessful transformations, Basic 
Local Alignment Search Tool (BLAST) was used to determine whether the strains being 
used carried the canonical TIGR4 allele SP0698, PNAG gene of interest, in their 
genomes and it was found that they did not carry the gene of interest (data not shown). 
PCR amplification using primers flanking the SP0698 gene locus showed PCR products 
of varying sizes (see Results Section III.d) (Figure 4). Transformation attempts with these 
strains were then abandoned, new strains were selected and PCR amplification was 
performed to confirm presence of the targeted PNAG gene locus in these strains.  
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The main problem encountered during competent cells production was low cell 
growth. In order for a DNA transformation to be successful, there must be a high volume 
of competent cells due to the low transformation frequency of S. pneumoniae, which has 
been reported to be as low as 10-7 in S. pneumoniae (Li, Thompson, & Lipsitch, 2014). 
This problem of low cell growth was remedied by several ways: switching to a different 
formulation of plastic culture tubes, using fresh reagents, and by incubating a slow-
growing strain at a lower temperature for a longer period of time. Early in the project, it 
was found that the use of polypropylene culture tubes inhibited bacterial growth. 
Switching to polystyrene culture tubes remedied the slow bacterial growth during the 
incubation period of competent cell production. Ensuring that the BSA used in the CM 
was new and acquired within 6 months also helped with producing a higher cell count 
and improved transformation reactions (data not shown). To improve the growth of the 
slow growing FJ003 strain, it was found that incubating the competent cells at 30°C for 
10 hours, instead of incubating at 37°C for 5 hours, yielded greater cell numbers and 
more successful transformation (data not shown).  
To further optimize the bacterial transformation procedure, it was found that 
doubling the amount of transforming DNA and competence-stimulating peptide (CSP) 
used improved transformation yields for strains FJ002 and FJ003 (data not shown). 
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III.b. PCR Showing Presence of PNAG Gene with Transposon Interruption 
As previously described, PCR was used to amplify DNA segments of the PNAG 
gene locus in S. pneumoniae. Gel electrophoresis was used to visualize the PCR products. 
PCR using primers (see Table 2) to amplify the PNAG gene locus in the wild type S. 
pneumoniae strains, 353, 1230, FJ002, and FJ003 yielded products that when visualized 
on a gel, showed bands corresponding to ~3.8 kb, the expected size of the functional 
PNAG gene (Figure 3). PNAG gene amplification of the S. pneumoniae strain 3195 (with 
parental strain 353 background), which contained the non-functional, transposon-
interrupted PNAG gene, showed a band of ~4.5 kb, the expected size (Figure 3). PNAG 
gene amplification of the PNAG mutants, FJ001, FJ004, FJ005, showed bands 
corresponding to ~4.5 kb, the expected size (Figure 3).  
 
Figure 3. PCR and Gel Electrophoresis Confirms Transformation of 
SP0698::Magellan5 Allele in S. pneumoniae Strains. Lanes 2-5: PCR of the wild type 
strains using primers flanking the SP0698 gene encoding normal PNAG show the 
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expected 3.8 kb amplicons. Lanes 6-9: PCR of the mutant strains using the same primers 
show the expected larger 4.5 kb amplicons indicating successful transformation with the 
gene locus SP0698 containing the Magellan 5 transposon. 
 
III.c. Canonical TIGR4 Allele of PNAG Was Not Successfully Detected in All 
Strains of S. pneumoniae 
The first series of transformations using non-vaccine serotype strains selected 
from laboratory clinical isolates were unsuccessful. PCR was used to evaluate whether 
these strains contained the functional PNAG gene locus within the genome. Contrary to 
what was expected, gel electrophoresis showed many bands of differing sizes (Figure 4). 
Further bioinformatic analysis showed none of the 11A serotype isolates in our 
nasopharyngeal (NP) collection contain this allele (data not shown).  
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Figure 4. Gel Electrophoresis Analysis of PCR Amplification of SP0698 gene in 11A 
and 35B Clinical Isolates Show Gene Segments of Different Sizes. Lanes 2-6 show 
PCR amplicons produced using primers that amplify an expected 3.8 kb segment of 
DNA. Lanes 8-12 show PCR amplicons produced using primers that amplify an expected 
2.7 kb segment of DNA. Note the bands of varying weights in strains 159, R34-3203, 
LE4018 and PT8037. Only strain 1230 shows band of expected size when amplified 
using primers that produce an expected 3.8 kb segment of DNA.  
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III.d. Indirect Immunofluorescence Showing Expression of PNAG Gene With 
Transposon Interruption 
Indirect immunofluorescence was used to assess the expression of the PNAG 
polysaccharide on the cell surface of the selected S. pneumoniae strains using 
fluorescent-labeled antibody probes targeting PNAG. Using fluorescent microscopy, anti-
PNAG antibodies found to have bound to the strains 1230, 159, R34-3203 and LE4018. 
Anti-PNAG antibodies were not detected bound to PT8037, an 11A serotype. There was 
no presence of anti-PNAG antibodies detected bound to FJ001, indicating transformation 
with SP0698::Magellan5 disrupted proper expression of PNAG (Figure 5).  
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Figure 5. Indirect Immunofluorescence Shows Variable Expression of PNAG in 11A 
and 35B Clinical Isolates and Lack of Expression in PNAG Mutant. Indirect 
immunofluorescence was used to show expression of PNAG on the cell surfaces of S. 
pneumoniae and confocal microscopy was used to visualize the fluorescent labels. (A) – 
(D) Anti-PNAG antibodies bound to PNAG molecules in strains 1230, 159, R34-3203, 
and LE4018. (E) Anti-PNAG antibodies were not bound to PT8037. (F) Anti-PNAG 
antibodies were not bound to PNAG transformation, FJ001. For each strain labeled A - F, 
upper left panel: nucleic acid stain (red=DNA); upper right: fluorescent antibody (green = 
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PNAG expression); lower left: phase contrast; lower right: composite of nucleic acid 
stain and antibodies (red and green).
III.e. Biofilm Assay Optimization 
The biofilm assay procedure used was adapted from a procedure designed by the 
Camilli laboratory (Munoz-Elias et al., 2008). In order to ensure reliability of the biofilm 
assay, amendments were made to the procedure. Glucose was added to the sBHI broth at 
final concentrations of 0% 1%, 2%, 3%, and 5% glucose to determine optimal glucose 
concentration at which the acapsular 2394 and 3195 strains produced the expected 
differential levels of biofilm formation. It was found that 5% glucose was the optimal 
concentration at which the acapsular 2394 strain produced more biofilm than strain 3195 
(data not shown), confirming the results in the Camilli biofilm study findings (Munoz-
Elias et al., 2008). 
The amount of time required for the incubation period to produce biofilm was 
found to be most optimal at 18 hours. It was found that incubation periods greater than 18 
hours resulted in dislodgement of biofilm matter from the wells during plate-washing 
(data not shown).  
The addition of the DAPI stain to the biofilm assay procedure added an additional 
component to more reliably assess whether the biomass produced by the bacteria in the 
96-well plates was actually biofilm. The DAPI stain was used to detect the presence of 
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DNA (intracellular or extracellular), which is thought to be an important component in 
bacterial biofilm (Figure 8) (Goodman et al., 2011).
III.f. Spectrophotometry Measurements of Optical Density Showed Difference in 
Initial Cell Growth Levels 
The biofilm assay was used to assess levels of biofilm production in the wild type 
and PNAG deficient strains. In order to compare the different strains, the initial cell 
growth density of each strain to be compared must not be significantly different. Using 
spectrophotometry to measure optical density at 595nm, it was found that there was no 
significant difference between strains 1230 and FJ001 and between strains FJ002 and 
FJ004 in initial grown cell density (Figure 6). However, there were significant differences 
found between strains 2394 and 3195 (P < 0.0001 Student’s t-test, N=8); 2394 and 3213 
(P < 0.0001 Student’s t-test, N=8); and FJ003 and FJ005 (P < 0.01 Student’s t-test, N=8).  
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Figure 6. Wild Type and Mutant Strains Show Differential Growth Rates. Wild type 
and mutant strains were grown in sBHI supplemented with 5% glucose in 96-well 
polystyrene plates and incubated for 18h at 37°C. Optical density was measured at 595 
nm. Significant differences were found in the initial cell growth between strains 2394 and 
3195 (P < 0.0001 Student’s t-test, N=8); and strains 2394 and 3213 (P < 0.0001 Student’s 
t-test, N=8). Initial cell growth between strains FJ003 and FJ005 was found to be 
significantly different (P < 0.01 Student’s t-test, N=8).  
* P < 0.01, Student’s t-test 
** P < 0.0001, Student’s t-test
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III.f.i. Crystal Violet Stain Showed Differential Levels of Biofilm Formation 
Between Wild Type and PNAG Mutant Strains of S. pneumoniae 
Crystal violet was used to stain cellular and extracellular biomass thought to be 
biofilm and optical density (OD) measurements were taken using spectrophotometry in 
order to determine levels of biofilm production in each of the S. pneumoniae strains. In 
the acapsular 2394 strain, the OD was found to be significantly greater than the acapsular 
3195 (P < 0.01 Student’s t-test, N=8) (Figure 7). Strain 2394 was also found to have an 
OD significantly greater than the acapsular 3213 strain (P < 0.0001 Student’s t-test, 
N=8). Comparisons between the encapsulated wild type strains (1230, FJ002, and FJ003) 
and the encapsulated strain 353 did not show a significant difference.
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Figure 7. Wild Type and Mutant Strains Show Differential Levels of Biofilm 
Formation. Following 18h of incubation, wild type and mutant strains were washed with 
deionized water, and remaining biofilm was fixed by air-drying and stained with 0.06% 
crystal violet. Following with 30% acetic acid, optical density was measured at 595 nm. 
Acapsular strain 2394 produced a significantly greater amount of biofilm than acapsular 
strain 3195 (P < 0.01 Student’s t-test, N=8).  
* P < 0.01 Student’s t-test 
** P < 0.0001 Student’s t-test
III.f.ii. DAPI Stain Showed Presence of DNA in The Biofilm
 DAPI was used to stain for DNA in the biofilm formed by the different S. 
pneumoniae strains in the 96-well polystyrene plates. Using fluorescence microscopy and 
objective analysis, it was found that DAPI concentrated more greatly to the acapsular 
2394 and acapsular 3195 strains than the 353, other encapsulated wild type strains, and 
the encapsulated PNAG mutant strains (Figure 8). However, the amount of fluorescent 
staining was noticeably lower in 3195 than in the acapsular 2394 strain. 
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Figure 8. Biofilm Formed by Wild Type and Mutant Strains Show Differential 
Levels of Detectable DNA. Wild type and mutant strains were incubated in 96-well 
tissue culture plates for 18 hours, fixed with 2% paraformaldehyde and stained with 
DAPI to detect DNA. Representative images were taken of each strain. Note that in 
comparison to the encapsulated strain TIGR4 GSK (wild type), the acapsular mutant 
strains 3185, 3195, and 3213 show a varied increase in DNA presence. 
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DISCUSSION 
 
There is very little known about poly n-acetyl glucosamine in S. pneumoniae, 
however previous research in Staphylococcus epidermidis has demonstrated its role in 
biofilm formation (Vuong et al., 2004). Additionally, studies in Staphylococcus aureus 
have demonstrated that increasing PNAG expression resulted in increased bacterial 
survival in the mouse bacteremia model and increased in vitro biofilm formation (Cerca 
et al., 2007). These findings taken together suggest that PNAG plays a role in 
establishing bacterial colonization through the formation of biofilm and thus greater 
pathogenicity in staphylococci. What is not known is whether PNAG is involved 
similarly in biofilm formation in Streptococcus pneumoniae, a bacterium related to 
staphylococci that is also a member of the Firmicutes phylum. The aim of this thesis was 
to confirm the reduced expression of PNAG following bacterial transformation with 
nonfunctioning PNAG allele and to assess in vitro biofilm formation levels by PNAG 
non-expressing strains of S. pneumoniae.  
In order to objectively assess the effects of PNAG, it was necessary to select S. 
pneumoniae strains of both vaccine and non-vaccine serotypes. 1230 (35B) and PT8090 
(16F) are both non-vaccine serotypes and MD5033 (19A) is a vaccine serotype. The use 
of both types of serotypes allowed for identifying possible serotype-related differences in 
the effects of PNAG on biofilm formation. PCR and gel electrophoresis were able to 
confirm successful transformation of SP0698::Magellan5 in 35B, 16F, and 19A serotypes 
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of S. pneumoniae based on the detection of the expected mutant allele size of 4.5 kb in 
comparison to the size of the expected wild type SP0698 allele of 3.8 kb (Figure 3). In 
order to more accurately confirm the successful transformation, genomic sequencing of 
the mutant strains would be needed.  
Based on our crystal violet and DAPI stain results, there does not appear to be a 
significant difference among the 16F and 19A serotypes in levels of biofilm formation 
(Figure 8). Although this may suggest that PNAG is independent of serotype, it should be 
noted that this biofilm assay was designed using an acapsular strain as the control for 
assessing normal levels of biofilm formation. It was found that the capsule produced a 
masking effect that concealed the effects of low biofilm-producing mutants during a 
large-scale biofilm formation screening of S. pneumoniae (Munoz-Elias et al., 2008). In 
order to unmask the effects of the capsule and to reveal the effects of the various gene 
mutations, the researchers conducted a second biofilm formation mutation screening 
using acapsular mutants. After removing the capsule, the gene locus encoding for PNAG 
was identified in this screen as one of the genes found to produce lower levels of biofilm 
in S. pneumoniae (acapsular strain only). 
Based on the design of the Camilli biofilm assay using crystal violet as a biofilm 
stain, our preliminary results did confirm the masking effects of the capsule. The biofilm 
assay optimization was performed to replicate the results that the Camilli laboratory 
found and to ensure reliability of the assay. It was found that when comparing the 
acapsular 3195 to the acapsular 2394 control strain, the 3195 did show a significant 
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reduction in crystal violet staining (Figure 7), suggesting a reduction in biofilm levels, 
which confirmed previously published findings (Munoz-Elias et al., 2008). The 
comparison between these two acapsular strains demonstrates that removing the capsule 
did reveal a significant difference in biofilm formation (P < 0.01 Student’s t-test, N=8), in 
which the PNAG non-expressing 3195 produced a significantly lower level of biofilm 
than the PNAG-expressing 2394 control strain. However, based on the results of the 
initial bacterial growth, these differences in biofilm formation could be attributed to 
bacterial growth differences. Similar initial bacterial growth should be demonstrated in 
each compared strain in order to more accurately conclude that differences in biofilm 
formation are not due to differences in bacterial growth rate. Replication of the biofilm 
assay with adjustments should be made in the future.  
When analyzing the results from the biofilm assay for the PNAG-deficient strains, 
it was found that there was no significant difference found between the PNAG mutants 
and their corresponding wild type strains. This finding was also expected because these 
strains were encapsulated, which prevented the biofilm assay from revealing differences 
that may be due to PNAG expression. With further research, acapsular mutants 
containing the PNAG mutant allele should be produced in order to appropriately evaluate 
the levels biofilm formation between the wild type and PNAG strains. If PNAG does play 
a role in biofilm formation, it would be expected that the acapsular PNAG mutant allele 
strains produce significantly lower levels of biofilm than the acapsular wild type strains 
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containing functional-expressing PNAG. This finding would confirm the role that PNAG 
plays in governing in vitro biofilm formation in S. pneumoniae.  
The initial PCR of the 11A isolates, R34-3203, LE4018, and PT 8037 showed 
bands of varying sizes when visualized using gel electrophoresis (Figure 4). This was 
especially apparent when primers designed to amplify shorter flanking regions of the 
SP0698 allele produced more amplicons. By minimizing specificity of the primers to 
annealing regions of the genome, gene segments of various sizes were amplified 
suggesting either multiple regions of homology to the SP0698 allele or that there is a 
gene encoding PNAG that is slightly different in sequence to the canonical TIGR4 
SP0698 allele. Further analysis of this finding using indirect immunofluorescence 
confirmed expression of PNAG in all but one of the 11A isolates (PT8037) (Figure 5). 
PCR findings indicated the presence of a different allele when compared to the canonical 
TIGR4 SP0698 in PT8037. Despite expression of PNAG in the other isolates without 
canonical TIGR4 SP0698, PT8037 appeared to not have detectable PNAG with our 
assay. This suggests that the sequence of this allele may be different enough to produce a 
molecule undetectable by the antibodies targeting the canonical PNAG molecule (Figure 
4). These results suggest that there may be variability in the SP0698 gene sequence and in 
the expression of PNAG in the 11A serotypes of S. pneumoniae.  
PNAG is currently being investigated as a potential vaccine target against S. 
pneumoniae because of its possible role in nasopharyngeal colonization. By 
demonstrating that PNAG plays an active role in biofilm formation and thus colonization, 
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it can be hypothesized that PNAG-deficient S. pneumoniae strains would exhibit reduced 
biofilm formation and therefore reduced ability to colonize the host nasopharynx. With 
reduced bacterial colonization, the transition from colonization to infection would also be 
reduced, ultimately minimizing the development of pneumococcal disease. The ability of 
PNAG to potentially influence disease development therefore makes it an important 
vaccine target candidate.  
As a target antigen, PNAG can be targeted for removal by the host immune 
system. In order to demonstrate the viability of PNAG as a vaccine target, immunological 
studies must be conducted. To investigate the innate immune response to PNAG, 
complement binding studies should be conducted to assess whether PNAG-deficient 
strains are able to produce changes in complement binding. Anti-PNAG antibody studies 
should also be conducted to investigate the active immune response to PNAG to 
investigate the effectiveness of antibody-dependent opsonization and clearance.  These 
studies would then be able to demonstrate whether PNAG antibodies are able to elicit 
strong immune responses and therefore its candidacy as a vaccine target.  
In order for a non-capsular vaccine to effectively target S. pneumoniae, it must be 
able to be detected with high specificity across all serotypes. However, the results 
showing varied anti-PNAG antibody binding in the 11A isolates demonstrates variability 
in the expression of PNAG, which suggests a possible variability of expression in other 
serotypes in the population. Therefore, targeting only the canonical TIGR4 PNAG 
molecule would then neglect the different wild type expressions of PNAG. In order to 
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circumvent this problem, the vaccine must be able to detect all possible expressions of 
PNAG. It is possible that variance in epitope structure could play a role, as a recent study 
in S. aureus has suggested. A study conducted in S. aureus has proposed that low-affinity 
antibody binding to PNAG could be due to epitope variation, which may also play a role 
in S. pneumoniae (Cerca et al., 2007).  Further research should be conducted to 
investigate the variability in expression of PNAG in S. pneumoniae.  
In conclusion, the results of this research project were able to confirm successful 
transformation of a mutant PNAG allele in non-vaccine and vaccine serotypes of S. 
pneumoniae. However genotype sequencing would be necessary to confirm more 
accurately. Further research is also necessary to assess levels of biofilm formation of the 
PNAG mutants using acapsular strains. Following that, immunological studies will be 
needed to assess the ability of PNAG to elicit immune responses using in vitro and in 
vivo methods. Animal studies should be conducted using PNAG mutants to assess its role 
in virulence. A novel finding in PNAG gene structure in S. pneumoniae was also 
discovered, providing a new avenue of research. These investigations would then better 
elucidate the role that PNAG plays in pathogenicity and its viability as a vaccine 
candidate.   
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